Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Issues
2012
June 2012, Vol 3, No 4
June 2012, Vol 3, No 4
The Value of Level I Pathways at US Oncology
By
Caroline Helwick
June 2012, Vol 3, No 4
Houston, TX—The use of the Level I Pathways Program at McKesson Specialty Health/US Oncology Network over the past 5 years has reduced treatment variability and resulting costs, according to Roy A. Beveridge, MD, chief medical officer, McKesson Specialty Health/US Oncology Network.
Read Article
Reimbursement Strategies Must Be Patient-Centered
June 2012, Vol 3, No 4
n an interview with the Association for Value-Based Cancer Care (AVBCC), Jennifer Malin, MD, PhD, Medical Director of Oncology at WellPoint, emphasized that patients should remain the central focus in novel or innovative reimbursement models.
Read Article
Cancer and Corporate America: Business as Usual?
By
Audrey Andrews
NCCN Conference
June 2012, Vol 3, No 4
Hollywood, FL—Is corporate America doing enough to promote optimal cancer care? The provision of insurance coverage alone is no longer sufficient for America’s workers.
Read Article
BRAF and MEK Inhibitors Make News at ASCO
By
Audrey Andrews
ASCO Annual Meeting
,
ASCO
June 2012, Vol 3, No 4
Chicago, IL—At the 2012 American Society of Clinical Oncology meeting, attendees flocked to sessions on the treatment of melanoma to hear about the next generation of agents that are building on the success achieved with the
BRAF
inhibitor vemurafenib (Zelboraf), and the immunotherapy drug ipilimumab (Yervoy), which have added new treatment options where, not long ago, none existed.
Read Article
Abiraterone Merits Consideration as New Standard Before Chemotherapy for Treatment of Prostate Cancer
ASCO Annual Meeting
,
ASCO
June 2012, Vol 3, No 4
Chicago, IL—Abiraterone acetate (Zytiga) delays disease progression when used with prednisone before chemotherapy in men with metastatic castration-resistant prostate cancer, said Charles J. Ryan, MD, Associate Professor of Clinical Med icine, Helen Diller Family Comprehensive Cancer Center at the University of California, San Francisco, who reported a planned interim analysis of a phase 3 study at the 2012 meeting of the American Society of Clinical Oncology.
Read Article
In Head-to-Head Comparison, Continuous Beats Intermittent Hormonal Therapy for Metastatic Prostate Cancer
By
Wayne Kuznar
ASCO Annual Meeting
,
ASCO
June 2012, Vol 3, No 4
In men with metastatic prostate cancer, especially those with minimal disease spread, continuous rather than intermittent hormonal therapy should be considered the preferred therapy, according to the results of a large multicenter phase 3 international trial.
Read Article
EMILIA: Trastuzumab Emtansine Prolongs Remission in Advanced Breast Cancer
By
Audrey Andrews
ASCO Annual Meeting
,
ASCO
June 2012, Vol 3, No 4
Chicago, IL—The novel antibody drug conjugate trastuzumab emtansine (T-DM1) significantly extended progression-free survival (PFS) and was very well tolerated in the first results of the international EMILIA trial, which were presented at the 2012 American Society of Clinical Oncology (ASCO) meeting.
Read Article
Phased Ipilimumab Improves PFS and OS in NSCLC
In the Literature
June 2012, Vol 3, No 4
Ipilimumab—added in a phased regimen to paclitaxel and carboplatin chemotherapy—increased progressionfree survival (PFS) and immune-related PFS in a randomized, double-blind, international, phase 2 study of previously untreated adult patients with non–small-cell lung cancer (NSCLC).
Read Article
Inotuzumab Ozogamicin Shows High Response Rate in Refractory/Relapsed ALL
In the Literature
June 2012, Vol 3, No 4
In a single-arm, phase 2 study, inotuzumab ozogamicin, a CD22 monoclonal antibody conjugate, showed potential utility as a monotherapy that may improve the often poor prognosis for patients with refractory or relapsed acute lymphocytic leukemia (ALL; Kantarjian H, et al.
Lancet Oncol
. 2012;13:403-411).
Read Article
New Reimbursement Policies Needed to Align Payment with Cancer Care Outcomes
In the Literature
June 2012, Vol 3, No 4
Current reimbursement policies for cancer chemotherapies do not ensure that the value and cost of therapies are commensurate with outcomes.
Read Article
Page 2 of 4
1
2
3
4
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Medication Assurance Programs, as Deceiving and Harmful as Alternate Funding Programs
Dawn Holcombe, MBA, FACMPE, ACHE
2.
Addressing Challenges to Adoption of Value-Based Agreements
Phoebe Starr
3.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma